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ABSTRACT
Objective: An efficient ultra-high performance liquid chromatographic (UHPLC or Infinity LC 1290) method has been developed and validated for the 
quantification of possible carcinogenic or genotoxic impurities in febuxostat drug substances and drug products at 18 µg/ml level.
Methods: This method includes the conclusion of four potential genotoxic impurities in febuxostat. The mobile phase is trifluoroacetic acid, 
acetonitrile, and water with linear gradient elution. The UHPLC column used for the analysis was zorbax RRHD eclipse plus C18 with a length of 
100 mm, internal diameter of 2.1 mm, and particle size of 1.8 µ.
Results: The limit of detection and limit of quantitation of the impurities are <0.1 (0.00001%) and 0.3 µg/ml (0.00003%) with respect to febuxostat 
test concentration of 1000 µg/ml, respectively. This method has been validated as per ICH guidelines Q2 (R1).
Conclusion: A rapid, cost-effective infinity LC method was wonderfully established for quantitative analysis of possible genotoxic impurities of 
febuxostat drug substance and drug products.
Keywords: Febuxostat, Genotoxic impurities, Ultra-high performance liquid chromatograph, Infinity-LC 1290, Validation.
INTRODUCTION
Febuxostat is a drug that hinders xanthine oxidase, thus plummeting 
production of uric acid in the consistency. It is employed in the 
discussion of chronic gout and hyperuricemia. Febuxostat was revealed 
by scientists at the Japanese Pharmaceutical Company Teijin in 1998. 
Teijin united the drug with TAP Pharmaceuticals in the US and Ipsen 
in Europe. Ipsen obtained a marketing endorsement for febuxostat 
from the European medicines agency in April 2008, Takeda obtained 
FDA approval in February 2009, and Teijin attained sanction from 
the Japanese “Pharmaceuticals and Medical Devices Agency” in 2011. 
Febuxostat is used to treat chronic gout and hyperuricemia [1]. The 
National Institute for Health and Clinical Excellence concluded that 
febuxostat is extra effective than usual dosages of allopurinol, but not 
more effective than higher doses of allopurinol [1]. Febuxostat is in the 
US pregnancy category C; there are no adequate and well-controlled 
studies in pregnant women [2].
The determination of febuxostat and its related compounds were 
performed by LC studies at the level of 1000 µg/ml or 0.10% w/w 
with respect to the target analyte concentration. As per the selection 
of synthetic route, the related compounds of febuxostat may be 
categorized as genotoxic or carcinogenic. Nowadays, the regulators 
were very much interested about the genotoxic impurities present 
in drug substances and drug products. They assert to have a control 
of potential genotoxic impurities in the synthetic drug process. The 
control of potential genotoxic impurities shall be provided based on the 
availability of the high sensitive chromatography method. This directs 
us to evolve a method for the genotoxic impurities of febuxostat in the 
drug substances and drug products using ultra-high performance liquid 
chromatographic (UHPLC).
Other subjects were explained about the determination of febuxostat 
was performed by liquid chromatograph coupled mass spectrometer 
(LCMS/MS) in human plasma [3-6], by LC-ultraviolet (UV) [7], by 
HPLC [8-10], by UPLC [11-13], and by UPLC/MS in dog plasma [14]. The 
related compounds of febuxostat were separated and determined at the 
level 0.10% w/w level or 1000 µg/ml level by UPLC in literature [13]. 
Hence, as to increase the sensitivity of the method using these four 
genotoxic impurities in febuxostat, the research work has been initiated 
which was grounded in the literature [13,15-24,26-29].
As per the literature survey of the febuxostat drug substances and 
drug products, no one has reported the infinity LC/UHPLC method for 
the quantification of probable genotoxic impurities in febuxostat at 
18 µg/ml level, and this is the novelty of the article.
Evaluation study of genotoxicity and carcinogenicity
From the appraisal study of genotoxic and carcinogenic impurities; 
imp-1, imp-2, imp-3, and imp-4 (Fig. 1) have been given an alert for 
potential carcinogen which was due to the presence of aldehyde 
functional group in its own structure of the molecule and also based on 
quantitative structure-activity relationship (QSAR). These alerts have 
been obtained from the Toxtree software and its version was 2.6.6. The 
recommended maximum daily dosage of febuxostat is about 80 mg. The 
threshold of toxicological concern limit could be 18.75 µg/ml as per 
the calculation provided in ICH guideline M7 and based on acceptable 




An Agilent - 1290 series UHPLC/infinity LC consisting of a 
binary/quaternary pump, column compartment (Zorbax RRHD eclipse 
plus C18 with 100 mm × 2.1 mm, 1.8 μm was used as a column), 
autoinjector, and a diode array detector (M/s. Agilent Technologies, USA). 
Water bath equipped with controller (Amkette Analytics, ANM alliance) 
was used for forced degradation studies. Photolytic studies were 
carried out in a photostability chamber (Thermolab Photo Stability 
Chamber, India). Thermal degradation works were accomplished in a 
hot air oven (Amkette Analytics, ANM alliance).
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Reagents and chemicals
Febuxostat, imp-1, imp-2, imp-3, and imp-4 (Fig. 1) were synthesized 
in chemistry lab, St. Peter’s university. Trifluoroacetic acid and 
acetonitrile were bought from Fisher Scientific. HPLC grade water was 
used, equipped with the Elga water purification system, Metrohm. 
Solutions preparation
Sample diluent
The sample diluent was prepared by mixing 300 ml of mobile Phase A 
solution and 700 ml of mobile Phase B solution. Filtered and degassed 
for usage of analysis.
Standard solution
The standard solution was prepared by exactly weighed and transferred 
about 18 mg each of imp-1, imp-2, imp-3, imp-4 and febuxostat in 100 ml 
volumetric flask; added 50 ml of sample diluent and ultra-sonicated for 
5 minutes. After sonication, the solution was made up to the mark with 
the sample diluent. Further, 10 ml of this solution was diluted into a 
100 ml volumetric flask and made up to the mark with sample diluent. 
Hence, the standard solution concentration was 18 µg/ml with respect 
to the test concentration of 1000 µg/ml febuxostat. The solution 
was centrifuged at 25°C for 30 minutes and filtered through 0.22 µm 
syringe filter and injected. By keeping, the same solution at ambient 
temperature for 24 hrs and it was used for solution stability study.
Sample solution
The sample solution was prepared by accurately weighed and 
transferred about 10000 mg of sample into 10 ml volumetric flask; 
added 5 ml of sample diluent and ultra-sonicated for 5 minutes. After 
sonication, the solution was made up to the mark with the sample 
diluent. The solution was centrifuged at 25°C for 30 minutes and 
filtered through 0.22 µm syringe filter and injected. By keeping, the 
same solution at ambient temperature for 24 hrs and it was used for 
solution stability study.
Method development
Several methods have been developed by HPLC and UPLC for the 
determination of febuxostat in the bulk and formulated products. Some 
developed methods for the quantification of febuxostat and its related 
compounds in the bulk and formulated products by UPLC [3,8-14,26]. 
These previously published research articles were failed to explain 
about the probable genotoxic impurities in febuxostat. Actually, the 
four impurities of febuxostat, which were mentioned in Fig. 1, were 
evaluated as potential genotoxic impurities using QSAR guidelines and 
these impurities were determined at 1500 µg/ml level in febuxostat by 
UPLC as per the literature work.
This mainly leads us to do further development of the method with 
four genotoxic impurities in febuxostat at the 18 µg/ml level by UHPLC. 
The same method [13] has been used for the initial development, 
but the sensitivity of the method was found at the very lowest level 
of those impurities of the literature work [13]. Hence, as to increase 
the sensitivity of the method, the mobile phase, pH and gradient 
composition have been modified accordingly. The pH of the mobile 
phase was maintained in the acidic region based on the literature [13], 
which was achieved by the addition of 1 ml of trifluoroacetic acid in 
1000 ml of water. The mass compatible mobile phase has been selected 
for the development and validation, because if any impurities were 
detected at the level of above or below limit of quantification (LOQ) in 
the sample which needs to be confirmed using UPLC-MS study.
Fortunately, these four potential genotoxic impurities were not 
present/not detected in the samples of drug substances and drug 
products. Hence, these samples were not screened by UPLC-MS. This 
could be the limitation of the present research work. These impurities 
have been eluted and separated well within the time of 6 minutes, but 
to ensure the consistency and specificity of the other impurities which 
was mentioned in the research article [26]; the gradient program has 
been slightly modified and extended up to 12 minutes. From this trial, 
the method was specific for all the impurities which have mentioned in 
the research article [26]. Furthermore, impurities of V and VI [26] were 
matching and other impurities were not matching with the present 
research work; hence, totally these four impurities considered for the 
research work. The results and comparisons of previously published 
articles were given in Table 1.
Concluded method for validation purpose
The UHPLC column was used Zorbax RRHD C18, 100 mm × 2.1 mm × 
1.8 µm. The mobile Phase A was diluted 1 ml of trifluoroacetic acid in 
1000 ml of water. The mobile Phase B was acetonitrile. The gradient 
program was mentioned as min/%B composition; 0.00/5.0, 0.80/5.0, 
2.00/25.0, 2.40/35.0, 6.00/50.0, 6.40/65.0, 8.00/80.0, 9.00/90.0, 
10.00/90.0, 10.20/5.0, and 12.00/5.0. The wavelength of detection 
was 320 nm and injection volume was 2 µl. The column compartment 
temperature was maintained at 45°C.
Method validation
Once chromatographic conditions were established; the method was 
validated in compliance with ICH guidelines. The following parameters 
of system suitability, specificity, linearity, precision, accuracy, limit of 
detection (LOD), LOQ, robustness, and forced degradation studies were 
performed for validation.
System suitability
The standard solution was prepared using standard as per the method. 
Moreover, six replicates are injected into the system.
Specificity
The specificity of the method was determined by comparing 
chromatograms obtained from standard, blank and that of forced 
degradation studies.
Fig. 1: The structure of potential genotoxic imurities and febuxostat. (a) ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-
5-carboxylate or imp-1, (b) ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate or imp-2, (c) 2-(3-formyl-4-
isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid or imp-3, (d) isobutyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-
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Linearity
The linearity of detector response was established by plotting a graph 
between concentrations versus average area responses of the analytes.
Precision
Six replicates injections of the standard solution were injected into the 
UHPLC system as considered as system precision. The precision of test 
method was evaluated by six preparations of spiked sample solutions 
with impurities of imp-1, imp-2, imp-3, and imp-4 from the same batch 
as considered as method precision.
Accuracy
A study of accuracy (recovery) was performed by spiking genotoxic 
impurities in drug substances and drug products. Samples were 
prepared as per the proposed method at QL-150% of the target test 
concentration.
LOD and LOQ limits
The LOD and LOQ were examined based on signal-to-noise ratio method 
as per the ICH guideline Q2 (R1). The signal to noise ratio for LOD is 3:1 
and the LOQ is 10:1. This was performed by performing the sequence 
of dilute solutions with a known concentration LOD and LOQ has been 
determined.
Robustness
Robustness of the method was investigated by varying the instrumental 
conditions such as flow rate (±0.1 ml/min), column oven temperature 
(±5°C), and the addition of trifluoroacetic acid in mobile phase 
Table 1: Comparative of results with the previously published research works







[3] LCMS/MS Internal 
standard
Febuxostat 0.5 pg/ml 1.00 ng/ml Liquid-liquid extraction Human 
blood 
serum
[8] HPLC External 
standard
Febuxostat 0.018 µg/ml 0.06 µg/ml Dissolve-inject Content
[9] HPLC External 
standard
Febuxostat 0.382 µg/ml 1.157 µg/ml Dissolve-inject Content
[10] HPLC External 
standard
Febuxostat 0.257 µg/ml 0.0783 µg/ml Dissolve-inject Content





































[12] UPLC External 
standard
Febuxostat 0.15 µg/ml 1.2 µg/ml Dissolve-inject Content










































LCMS/MS: Liquid chromatograph coupled mass spectrometer, HPLC: High performance liquid chromatography, UPLC: Ultra performance liquid chromatograph, 
UPLCMS/MS: Ultra performance liquid chromatography coupled mass spectrometer
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(±0.2 ml). The standard solution was prepared and analyzed as per the 
test procedure monitored the system suitability results.
Forced degradation studies
Acid degradation studies
Accurately weighed and transferred about 50,000 mg of sample into a 
50 ml of volumetric flask. Added 30 ml of diluent and 10 ml of 0.4 N 
HCl was added and refluxed at 60°C for 24 h and neutralized with 0.4 
N NaOH. After the exposure, the resultant solution was made up to the 
mark with diluent. The solution was centrifuged at 25°C for 30 min and 
filtered through 0.22 µm syringe filter and injected into the system, and 
chromatograms were recorded to assess the stability of the sample.
Alkali degradation studies
Accurately weighed and transferred about 50,000 mg of sample into a 
50 ml of volumetric flask. Added 30 ml of diluent and 10 ml of 0.4 N 
NaOH was added and refluxed at 60°C for 24 hrs and neutralized with 
0.4 N HCl. After the exposure, the resultant solution was made up to the 
mark with diluent. The solution was centrifuged at 25°C for 30 minutes 
and filtered through 0.22 µm syringe filter and injected into the system, 
and chromatograms were recorded to assess the stability of the sample.
Oxidative degradation
Accurately weighed and transferred about 50,000 mg of sample into a 
50 ml of volumetric flask. Added 30 ml of diluent and 10 ml of 3% H2O2 
was added and kept at room temperature for 24 hrs. After the exposure, 
the resultant solution was made up to the mark with diluent. The 
solution was centrifuged at 25°C for 30 minutes and filtered through 
0.22 µm syringe filter and injected into the system, and chromatograms 
were recorded to assess the stability of the sample.
Dry heat degradation
Accurately weighed and spread 10 g of sample in a dried Petri dish 
uniformly (maximum of 5 mm thickness). Placed the dish in an 
oven at 60°C for 7 days without vacuum. Recorded the weight (petri 
dish + sample) and noted the appearance before and after the stress 
test. Calculated percent change for the weight of sample. Weighed 
and transferred about 50,000 mg of stressed sample into a 50 ml of 
volumetric flask. After the exposure, the resultant solution was made 
up to the mark with diluent. The solution was centrifuged at 25°C for 
30 minutes and filtered through 0.22 µm syringe filter and injected into 
the system, and chromatograms were recorded to assess the stability 
of the sample.
Photostability studies
Weighed and transferred about 50,000 mg of exposed sample into two 
50 ml of quartz volumetric flasks and the solution was made up to the 
mark with diluent. One quartz volumetric flask was fully covered with 
aluminum foil and labeled as control sample solution, and another 
quartz volumetric flask was kept without covering aluminum foil and 
marked as stressed sample solution. Placed the tightly sealed flask in a 
suitable chamber and irradiate first under fluorescent light for a total 
exposure of 1.2 × 106 Lux hours, and then under UV fluorescent light 
for a total exposure of 200 W.hr/m2. The solutions were centrifuged 
at 25°C for 30 minutes and filtered through 0.22 µm syringe filter and 
injected into the system, and chromatograms were recorded to assess 
the stability of the sample.
RESULTS AND DISCUSSION
Different chromatographic conditions were employed for the analysis 
of febuxostat in both bulk and pharmaceutical dosage forms. The 
comparative results of previously published articles were given in 
Table 1.
The standard solution was injected repeatedly and performed the 
calculation of % relative standard deviation (RSD) for each peak and 
values were obtained was <5%. This indicates that the equipment 
was accurate and fit for study. The system precision results have been 
given in Table 2. The Chromatographs of blank and standard have been 
shown in Fig. 2.
The %RSD for the content of imp-1, imp-2, imp-3, and imp-4 was 
obtained below 2%. The %RSD for content impurities was within 3% 
for intermediate precision which was performed by different analysts, 
column, instrument, and day. This result shows that the method was 
precise. Table 3 shows the results of method precision data.
The LOD for imp-1, imp-2, imp-3, imp-4 and febuxostat were 0.070, 
0.076, 0.080, 0.070 and 0.073 µg/ml, respectively. The LOQ for imp-1, 
Fig. 2: (a and b) Chromatograms of blank and standard solution
a
b
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imp-2, imp-3, imp-4 and febuxostat were 0.21, 0.23, 0.24, 0.21 and 
0.22 µg/ml, respectively. The LOD and LOQ results indicated that the 
method was most sensitive when compared to the reported methods 
shown in Table 1.
The correlation coefficient values have been shown in Tables 4-8. The 
linearity graphs were shown in Figs. 3-7. The values of the correlation 
coefficients were almost equal to one; this indicates that the developed 
method was linear. The regression results indicate that the validated 
method was linear over the total concentration and it was satisfactory 
for its concentration range from LOQ to 150%. The percentage of bias 
was calculated by multiplying the slope with 100 and then the resultant 
was divided by the reference value, which can be considered as the area 
response obtained at the 100% level. The calculated % of bias values 
indicates that the method was linear and it was very close to the origin 
or close to the ideal theoretical value.
The accuracy percentage for imp-1, imp-2, imp-3 and imp-4 were 
85-105% of drug substance and drug products. This result indicates 
that the method was accurate and appropriate as the mean accuracy 
value was within the limit (80-120%).
The specificity of the method was demonstrated by the peak purity 
(i.e., the purity angle is lesser than the purity threshold) using the 
diode array detector for degraded samples. The peak purity analysis 
was homogeneous for imp-1, imp-2, imp-3, and imp-4. There was no 
interference was observed from blank peaks and impurities. There was 
no secondary peak aroused from forced degraded samples. The results 
of forced degradation study indicate that the method was stability 
indicating and the impurities, viz., imp-1, imp-2, imp-3 and imp-4 
were not the degradation impurities, and these are process related 
impurities only.
By carefully varying in chromatographic conditions the resolution 
between febuxostat, imp-1, imp-2, imp-3 and imp-4 were evaluated. 
The resolution between impurities and febuxostat was obtained >1.8 
in all the varied chromatographic conditions carried out (flow rate, the 
addition of trifluoroacetic acid and column temperature). The result of 
robustness analysis shows that the method was considered robust.
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Table 2: System precision results of imp-1, imp-2, imp-3, imp-4 
and febuxostat
Injection Area observed
Imp-1 Imp-2 Imp-3 Imp-4 Febuxostat
1 145,204 109,528 92,163 97,921 65,121
2 144,956 110,785 93,001 97,810 68,265
3 145,060 111,527 92,964 97,777 69,842
4 145,329 112,328 92,763 97,707 70,798
5 145,239 111,833 93,521 97,917 71,827
6 145,110 112,045 92,661 97,811 72,287
Mean 145,150 111,341 92,846 97,824 69,690
SD 134.32 1033.69 447.48 82.85 2663.39
%RSD 0.09 0.93 0.48 0.08 3.82
Limit RSD should be<15%
Imp: Impurity, SD: Standard deviation, RSD: Relative standard deviation
Table 3: Method precision results of imp-1, imp-2, imp-3 and imp-4
Preparation Imp-1 content (µg/ml) Imp-2 content (µg/ml) Imp-3 content (µg/ml) Imp-4 content (µg/ml)
1 17.552 18.025 17.956 18.112
2 17.668 18.158 17.865 18.251
3 17.023 18.026 17.952 17.996
4 17.258 18.251 17.874 18.665
5 17.325 18.036 18.025 17.953
6 17.125 18.325 18.001 17.992
Mean 17.3 18.1 17.9 18.2
SD 0.25 0.13 0.07 0.27
%RSD 1.4 0.7 0.4 1.5
Limit RSD for content should be<5%
Imp: Impurity, SD: Standard deviation, RSD: Relative standard deviation
Fig. 3: Linearity graph for imp-1
Fig. 4: Linearity graph for imp-2
Fig. 5: Linearity graph for imp-3
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drug substance and drug products. The method was found to be specific 
and truthful with attired and constant recoveries. The valid method 
may be used for the regular analysis of the determination of potential 
genotoxic impurities of febuxostat drug substances and drug products 
in quality control laboratories.
REFERENCES
1. Febuxostat for the Management of Hyperuricemia in People with Gout 
(TA164). Ch. 4. Consideration of the Evidence. Available from: https://
www.nice.org.uk/guidance/ta164/chapter/4-consideration-of-the-
evidence.
2. ULORIC (Febuxostat) Tablet for Oral Use Initial U.S. Approval; 
2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/
label/2009/021856lbl.pdf.
3. Chandu BR, Kanala K, Hwisa NT, Katakam P, Khagga M. 
Bioequivalance and pharmacokinetic study of febuxostat in human 
plasma by using LC-MS/MS with liquid liquid extraction method. 
Table 4: Linearity data of imp-1
Sample % Level Concentration (µg/ml) Peak response
1 LOQ 0.21 4385
2 50 9.0 48,745
3 80 14.5 77,380
4 100 18.1 96,529
5 120 21.6 115,521








LOQ: Limit of quantification and each % level injected twice
Table 5: Linearity data of imp-2
Sample % Level Concentration (µg/ml) Peak response
1 LOQ 0.23 2800
2 50 9.68 34,200
3 80 15.50 52,396
4 100 19.36 68,000
5 120 23.24 86,522








LOQ: Limit of quantification and each level injected twice
Table 6: Linearity data of imp-3
Sample % Level Concentration (µg/ml) Peak response
1 QL 0.24 3727
2 50 9.108 29,639
3 80 14.562 48,979
4 100 18.216 60,597
5 120 21.852 73,121








LOQ: Limit of quantification and each level injected twice
Table 7: Linearity data of imp-4
Sample % Level Concentration (µg/ml) Peak response
1 QL 0.21 2890.5
2 50 8.86 29,183.6
3 80 14.16 48,165.6
4 100 17.71 61,301.2
5 120 21.25 72,133.0








LOQ: Limit of quantification and each level injected twice
Table 8: Linearity data of febuxostat
Sample % Level Concentration (µg/ml) Peak response
1 QL 0.22 2845.3
2 50 9.27 31,691.8
3 80 14.83 50,280.8
4 100 18.54 64,650.6
5 120 22.24 79,327.5








LOQ: Limit of quantification and each level injected twice
Fig. 7: Linearity graph for febuxostat
CONCLUSION
A swift, economical infinity LC method was magnificently established 
for quantitative analysis of possible genotoxic impurities of febuxostat 
Fig. 6: Linearity graph for imp-4
Asian J Pharm Clin Res, Vol 10, Issue 1, 2017, 324-330
 Balaji and Sultana 
330
Springerplus 2013;2(1):194.
4. Shi Z, Liu J, Hu XJ, Tu JZ. Development of a simple LC-MS/MS 
method for the determination of febuxostat in human plasma and its 
application to a bioequivalence study. Pharmazie 2013;68(6):396-400.
5. Vaka VR, Inamadugu JK, Pilli NR, Ramesh M, Katreddi HR. A sensitive 
LC-MS/MS method for the quantification of febuxostat in human 
plasma and its pharmacokinetic application. Biomed Chromatogr 
2013;27(11):1406-12.
6. Lukram O, Parmar S, Hande A. Determination of febuxostat in human 
plasma using ultra-performance liquid chromatography tandem mass 
spectrometry. Drug Test Anal 2013;5(6):492-9.
7. Younes KM, El-Kady EF, Elzanfaly ES. Determination of febuxostat 
in human plasma using RP-LC-UV method. J Chromatogr Sci 
2016;54(6):1022-7.
8. Rao KN, Ganapaty S, Rao LA. Development and validation of RP-
HPLC method for estimation of febuxostat in bulk and tablet dosage 
form. Int J Res Pharm Chem 2012;2(4):1104-8.
9. Ravisankar P, Rani AK, RamanaVK, Gowthami S. Development 
and validation of rapid RP - HPLC method for the determination 
of febuxostat (a non-purine selective xanthine-oxidase/xanthine-
dehydrogenase inhibitor) in bulk and pharmaceutical dosage form. 
World J Pharm Pharm Sci 2015;4(9):1046-61.
10. Mukthinuthalapati MA, Bandaru SP, Bukkapatnam V, Mohapatro C. 
Development and validation of a stability-indicating RP-HPLC method 
for the determination of febuxostat (a xanthine oxidase inhibitor). 
J Chromatogr Sci 2013;51(10):931-8.
11. Molleti S, Rao V, Jayaveera KN. A stability indicating RP-UPLC 
method for estimation of febuxostat and its impurities in bulk drugs and 
pharmaceutical dosage forms. Am J Pharm Tech Res 2013;3(2):405-22.
12. Sahu K, Shaharyar M, Siddiqui SA. Establishment of the inherent 
stability of febuxostat and development of a validated stability-
indicating method by UPLC according to ICH requirement. Med Chem 
Res 2013;22(4):1641-7.
13. Musirike MR, Reddy HK, Mallu UR. Development and validation of 
reverse phase-ultra performance liquid chromatographic method for 
estimation of related substances in febuxostat drug substance. Pharm 
Anal Acta 2015;6(10):1-6.
14. Zhang T, Sun Y, Zhang P, Gao J, Wang S, He Z. Ultra-performance 
liquid chromatography-tandem mass spectrometry method for the 
determination of febuxostat in dog plasma and its application to a 
pharmacokinetic study. Biomed Chromatogr 2013;27(2):137-41.
15. Pharmaceutical Development Q8(R2). Available from: http://www.
ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/
Q8_R1/Step4/Q8_R2_Guideline.pdf.
16. Vogt FG, Kord AS. Development of quality-by-design analytical 
methods. J Pharm Sci 2011;100(3):797-812.
17. Reid GL, Morgado J, Barnett K, Harrington B, Wang J, Harwood J, et al. 
Analytical quality by design (AQbD) in pharmaceutical development. 
Am Pharm 2013;16:49-59.
18. Debrus B, Guillarme D, Rudaz D. Improved quality-by-design 
compliant methodology for method development in reverse-phase 
liquid chromatography. J Pharm Biomed Anal 2013;84:215-23.
19. Validation of Analytical Procedures: Text and Methodology Q2(R1). 
Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_
Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.
20. Preventing Occupational Exposure to Antineoplastic and Other 
Hazardous Drugs in Health Care Settings Safety and Health, DHHS 
(NIOSH). Available from: https://www.cdc.gov/niosh/docs/2004-165/.
21. OECD Quantitative Structure-Activity Relationships Project [(Q)
SARs]. Available from: http://www.oecd.org/chemicalsafety/testing/
oecdquantitativestructure-activityrelationshipsprojectqsars.htm.
22. Roy K, Kar S, Das RN. Understanding the Basics of QSAR for 
Applications in Pharmaceutical Sciences and Risk Assessment. 
New York: Academic Press, Elsevier; 2015.
23. Stability Testing: Photostability Testing of New Drug Substances 
and Products Q1B. Available from: http://www.ich.org/fileadmin/
Public_Web_Site/ICH_Products/Guidelines/Quality/Q1B/Step4/Q1B_
Guideline.pdf.
24. Assessment and Control of DNA Reactive (Mutagenic) Impurities in 
Pharmaceuticals to Limit Potential Carcinogenic Risk M7. Available 
from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Multidisciplinary/M7/M7_Step_4.pdf.
25. Available from: http://www.drugbank.ca/drugs/DB04854.
26. Ravi P, Shanmugam V, Lahoti AM, Deepthi PS, Innareddy V, Rao S, 
et al. Investigation of various impurities in febuxostat. Pharm Technol 
2014;38(9):1-6.
27. Balaji N, Sayeeda S. Trace level determination and quantification of 
potential genotoxic impurities in dasatinib drug substance by UHPLC/
infinity LC. Int J Pharm Pharm Sci 2016;8(10):209-16.
28. Mercy R, Suja R, Caroling G, Tiwari S. In vitro evaluation of 
antioxidant, antimicrobial, anticancer activities and characterization of 
Brassica oleracea. Var. Bortrytis. L synthesized silver nanoparticles. Int 
J Pharm Pharm Sci 2013;5(4):239-51.
29. Manisha B, Priyanka P. Development and evaluation of paclitaxel 
loaded nanoparticles using 24 factorial design. Int J Curr Pharm Res 
2015;7(2):64-72.
